M4ND
Published March 10, 2026 | Version v1
Dataset Open

In silico Modeling for Small Molecule PRMT6 Inhibitors for the Treatment of Spinal Bulbar Muscular Atrophy (SBMA)

Authors/Creators

  • 1. Structural Genomics Consortium (SGC)
  • 2. Variational AI
  • 3. University Health Network (UHN)
  • 4. Enamine
  • 5. Northeastern University
  • 6. Agora Open Science Trust

Description

Spinal Bulbar Muscular Atrophy (SBMA), or Kennedy’s disease, is a rare, inherited neuromuscular disorder that leads to progressive muscle degeneration, weakness, and twitching. While it affects approximately 1 in 100,000 individuals worldwide, currently, there are no approved treatments for SBMA, leaving a substantial unmet medical need. 

Our program focuses on developing a novel therapeutic approach targeting PRMT6, a co-activator of the Androgen Receptor (AR) implicated in SBMA progression. The aim is to design a highly selective, brain-penetrant PRMT6 inhibitor targeting an allosteric site on the enzyme. Preliminary studies have shown that inhibiting PRMT6 reduces mutant AR activity and improves motor function in disease models. 

Here, we employ AI-guided in silico modeling to optimize the PRMT6 probe scaffold SGC6870 as a potential therapeutic for the treatment of  SBMA. This workflow integrates computational drug design, medicinal chemistry, and molecular biology, with subsequent in vitro and in vivo ADME optimization of prioritized compounds.

Table of key terms and definitions:

Key term

Definition 

PRMT6

Protein arginine methyltransferase 6, a transcriptional co-regulator

Androgen receptor (AR)

Type of nuclear receptor that is activated by binding any of the androgenic hormones, including testosterone and dihydrotestosterone, in the cytoplasm and then translocating into the nucleus

SBMA 

X-linked, slowly progressive neuromuscular disorder that affects adult males, typically presenting with muscle weakness, bulbar dysfunction, and endocrine abnormalities

SGC6870

A potent, selective and cell active allosteric inhibitor of PRMT6

S-adenosyl-L-methionine (SAM)

Methyltransferase cofactor

SAR

Structure activity relationship

ADME

Absorption, Distribution, Metabolism and Excretion

DMPK

Drug metabolism and pharmacokinetics

 

 

Notes

𝐀𝐛𝐨𝐮𝐭 𝐀𝐠𝐨𝐫𝐚 𝐎𝐩𝐞𝐧 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐓𝐫𝐮𝐬𝐭

Agora Open Science Trust is a Canadian charity whose mission is to accelerate the discovery and development of affordable new medicines through open science. Agora’s first initiative – M4K Pharma (‘Medicines for Kids’) – is using open science to drive preclinical and clinical development of a novel ALK2 inhibitor for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare pediatric brain cancer. Agora’s pipeline of collaborative open science drug discovery programs has recently expanded to include programs for Spinal Bulbar Muscular Atrophy (SBMA), a rare genetic neuromuscular disorder, and Primary Sclerosing Cholangitis (PSC), a rare liver disease — both of which currently have no approved treatment.

Agora continues to welcome collaborative funding partners whose support will help advance M4K2009 into clinical evaluation and sustain its mission to develop affordable medicines through open science.
You can support its mission at https://www.agoraopensciencetrust.org/donate-to-our-mission

Notes

Funding acknowledgement:

We gratefully acknowledge the generous support of our funders and donors, whose contributions made this work possible: Funding from Krembil Foundation, Conscience and Kennedy’s Disease Association 

Notes

Note: Author names are presented alphabetically. 

Files

SGC6870_Description .pdf

Files (1.6 MB)

Name Size Download all
md5:c0ba7df20019374fbca29b674967cd65
684.2 kB Download
md5:411c85dbf59e3c3984f77058cfd99bc8
950.5 kB Preview Download